Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04671329 · ClinicalTrials.gov registry record · NA
A Prospective, Multi-site Clinical Study to Collect User Feedback Using Affirm® Contrast Biopsy
A NA study, sponsored by Hologic.
- Completed
- Registry status
- NA
- Development phase
- 67
- Enrollment target
NCT04671329 is a NA study that has completed, run by Hologic. The registered enrollment target is 67 participants.
The verdict
NCT04671329, a NA study, has completed, sponsored by Hologic.
- COMPLETED
- Registry status
- NA
- Development phase
- 67 participants
- Enrollment target
Study Summary
Currently, if a radiologist finds a suspicious lesion seen only on a diagnostic Contrast Enhanced Digital Mammography (CEDM) exam requiring biopsy the biopsy procedure would likely be performed with MRI guidance because there are currently limited solutions to biopsy with CEDM guidance. Affirm Contrast Biopsy will provide an additional solution to biopsy/localize lesions found by using a CEDM imaging modality.
Interventions
- DEVICE Affirm Contrast Biopsy procedure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2021-03-05 |
| Est. Completion | 2022-08-18 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04671329
The ClinicalTrials.gov registry entry for NCT04671329 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hologic, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Affirm Contrast Biopsy procedure is the first listed.
NCT04671329 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04671329 about?
NCT04671329 is a clinical study titled "A Prospective, Multi-site Clinical Study to Collect User Feedback Using Affirm® Contrast Biopsy". Currently, if a radiologist finds a suspicious lesion seen only on a diagnostic Contrast Enhanced Digital Mammography (CEDM) exam requiring biopsy the biopsy procedure would likely be performed with MRI guidance because there are currently limited solutions to biopsy with CEDM guidance. Affirm Contr...
What is the current status of trial NCT04671329?
This trial is currently completed. It is a NA study. The enrollment target is 67 participants. The study started on 2021-03-05. Estimated completion is 2022-08-18.
What interventions are being tested in trial NCT04671329?
The interventions under investigation include: Affirm Contrast Biopsy procedure (DEVICE).
Who is sponsoring clinical trial NCT04671329?
This trial is sponsored by Hologic, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.